In a study conducted by Chiappinelli et al.,80 it was demonstrated that the DNMT inhibitor 5‐Azacytidine (5‐aza‐cr) enhanced the sensitivity of nonimmunogenic melanoma cells to anti‐CTLA‐4 therapy and resulted in a reduction in tumor growth in immunocompetent mice. This evidence concerns the gene CTLA4 and melanoma.